|
Patent landscape, scope, and claims summary: |
Analysis of United States Patent 4,024,233
United States Patent 4,024,233, titled "Process for the Preparation of a Proteinaceous Substance," issued on May 17, 1977, to Genentech, Inc. The patent claims a process for the recombinant production of proteinaceous substances using microbial hosts. Specifically, it describes a method to produce human growth hormone in a bacterial organism. The core of the invention involves inserting a gene encoding a desired protein into a plasmid, introducing this recombinant plasmid into a suitable microorganism (such as Escherichia coli), and then culturing the microorganism under conditions that promote the expression of the gene and the production of the protein.
What is the core inventive concept of US Patent 4,024,233?
The central inventive concept of US Patent 4,024,233 is the direct expression of eukaryotic genes, specifically mammalian genes, in prokaryotic organisms to produce functional protein products. Prior to this patent, the expression of complex eukaryotic proteins in bacteria was considered technically infeasible due to fundamental biological differences, including the absence of post-translational modification machinery in bacteria and the different codon usage between species.
The patent’s claims focus on:
- A method for producing a proteinaceous substance: This involves using a host microorganism that has been genetically modified.
- Recombinant DNA: The core of the modification is the introduction of foreign DNA, specifically DNA encoding the protein of interest, into the host. This foreign DNA is typically carried on a plasmid.
- Microbial host: The patent specifies the use of microorganisms, including bacteria, as the production system.
- Expression of the foreign gene: The process requires the host organism to transcribe and translate the inserted gene into the desired protein.
This breakthrough enabled the large-scale, cost-effective production of valuable therapeutic proteins that were previously difficult or impossible to isolate from natural sources in sufficient quantities or purity.
What are the key claims and scope of protection for US Patent 4,024,233?
US Patent 4,024,233 contains several claims defining the scope of its protection. The most significant claims relate to the process of producing proteinaceous substances using recombinant DNA technology in microbial hosts.
Key Claims Breakdown:
-
Claim 1: This is the broadest claim and defines a method for producing a proteinaceous substance. It involves:
- Culturing a host microorganism.
- The microorganism contains a recombinant deoxyribonucleic acid molecule.
- This recombinant molecule is capable of causing the microorganism to produce the proteinaceous substance.
- The proteinaceous substance is the same as a naturally occurring proteinaceous substance encoded by a eukaryotic gene.
-
Claim 2: This claim narrows Claim 1 by specifying that the host microorganism is a prokaryote.
-
Claim 3: This claim further specifies the host microorganism as Escherichia coli.
-
Claim 4: This claim focuses on the composition of matter, claiming a bacterial cell transformed with a recombinant deoxyribonucleic acid molecule. This molecule encodes a eukaryotic gene and is capable of expressing the gene.
-
Claim 5: This claim adds a limitation to Claim 4, specifying that the eukaryotic gene is derived from a mammalian cell.
-
Claim 6: This claim specifically mentions the production of human growth hormone as an example of the proteinaceous substance.
Scope of Protection:
The patent protects the fundamental process of using genetically engineered bacteria to produce mammalian proteins. This includes:
- The method of creating and culturing recombinant bacteria that express foreign genes.
- The transformed bacterial cells themselves, if they are capable of producing the protein.
The patent's broad claims established foundational protection for the entire field of recombinant protein production in bacteria. This has had significant implications for the development and commercialization of numerous biopharmaceuticals.
What is the historical significance and impact of US Patent 4,024,233?
US Patent 4,024,233 is widely recognized as a foundational patent in the field of biotechnology. Its issuance marked a paradigm shift in drug development and manufacturing, enabling the commercialization of therapeutic proteins that were previously scarce or unattainable.
Key Impacts:
- Enabling Production of Biologics: The patent provided the legal framework for the industrial-scale production of recombinant proteins such as insulin, growth hormone, and interferons. Before this technology, these proteins were extracted from animal sources or human cadavers, which were expensive, unreliable, and posed safety risks.
- Genentech's Early Dominance: The patent was a cornerstone of Genentech's early success and established its position as a leader in the burgeoning biotechnology industry. It provided a competitive advantage that allowed the company to develop and market groundbreaking therapies.
- Foundation for Subsequent Patents: While broad, the patent's claims also spurred further innovation and led to a wave of subsequent patents covering improvements to the recombinant DNA process, specific gene sequences, novel expression vectors, and purification methods.
- Litigation and Licensing: The broad scope of the patent led to significant licensing agreements and, in some cases, complex litigation, as companies sought to utilize or navigate around its protected technology. The dispute over the infringement of this patent by the production of human growth hormone by other companies was a landmark case in patent law.
- Economic Transformation: The ability to produce biologics efficiently and at scale revolutionized the pharmaceutical market, leading to new treatment options for a wide range of diseases and generating billions of dollars in revenue for the biotechnology sector.
The patent's impact is not merely historical; the principles it protects continue to underpin much of modern biopharmaceutical manufacturing.
What were the primary challenges and controversies surrounding US Patent 4,024,233?
The revolutionary nature of US Patent 4,024,233 also brought about significant challenges and controversies, primarily related to its broad scope and the novelty of the technology it claimed.
Key Challenges and Controversies:
- Obviousness and Prior Art: A recurring challenge for patents in rapidly advancing fields is the determination of whether the claimed invention was truly novel and non-obvious. Competitors and later legal challenges questioned whether the invention was sufficiently distinct from existing scientific knowledge and techniques available at the time of filing. The debate often centered on the interpretation of "obvious to a person skilled in the art."
- Enablement and Written Description: Patent law requires that an invention be described in sufficient detail to enable someone skilled in the art to make and use it. For a groundbreaking patent like this, questions arose about whether the patent adequately described the process and supported the broad claims made.
- Infringement Disputes: The broad claims of the patent inevitably led to disputes over infringement. Companies that developed their own recombinant DNA technologies or produced recombinant proteins were often accused of infringing on Genentech's patent.
- One notable area of contention was the production of recombinant human growth hormone (somatropin). Other companies sought to market their versions, leading to legal battles.
- Disputes also arose regarding specific methods of gene insertion, expression optimization, and purification processes.
- Licensing Negotiations: The immense commercial value of the technology made licensing negotiations highly contentious. Companies wanting to use the patented process or produce patented proteins often faced high licensing fees or the risk of litigation if they proceeded without a license.
- Public Access vs. Commercial Exclusivity: As with many foundational patents, there was an inherent tension between the patent holder's right to exclusive commercialization and the public interest in accessing potentially life-saving therapies. The duration of patent protection (initially 17 years from issuance, later changed to 20 years from filing) was seen by some as limiting access to essential medicines for too long.
- Evolving Scientific Landscape: The rapid pace of scientific discovery meant that the technology covered by the patent was constantly being built upon and improved. This created a complex legal landscape where it could be challenging to delineate the exact boundaries of the original patent's protection against newer, related innovations.
These challenges highlight the complex interplay between scientific innovation, patent law, and commercial interests in the biotechnology sector.
What is the current status and enforceability of US Patent 4,024,233?
United States Patent 4,024,233, issued in 1977, has long since expired. Under United States patent law as it existed at the time of issuance, patents had a term of 17 years from the date of grant.
Expiration Details:
- Issue Date: May 17, 1977
- Expiration Date: May 17, 1994 (17 years from the issue date)
Current Status:
As of May 18, 1994, US Patent 4,024,233 is in the public domain. This means that:
- No Exclusive Rights: No entity, including Genentech, Inc. or its successors, holds exclusive rights to the claimed inventions.
- Freedom to Operate: Any individual, company, or research institution is free to practice the methods and use the technology claimed in this patent without requiring a license or facing infringement claims based on this specific patent.
- Prior Art Reference: The patent remains a significant piece of prior art. It serves as a foundational reference for subsequent patent applications and is considered in the examination of new inventions in the field of recombinant DNA technology.
Enforceability:
Since the patent has expired, it is no longer enforceable. Claims of infringement are not legally actionable for this patent. However, the innovations it pioneered have led to a vast number of subsequent patents covering more specific aspects of recombinant protein production, gene expression, vector design, and therapeutic applications. These later patents may still be in force and subject to enforceability.
The expiration of this patent has democratized the fundamental process it protected, allowing for wider adoption and further innovation in the biopharmaceutical industry.
What are the key takeaways from the analysis of US Patent 4,024,233?
- US Patent 4,024,233 protects the foundational process of using recombinant DNA technology in microbial hosts to produce proteinaceous substances, enabling the mass production of therapeutic proteins.
- The patent's claims focus on the method of genetically modifying microorganisms to express eukaryotic genes and the resulting transformed cells.
- It was a landmark patent that revolutionized the pharmaceutical industry by making the production of previously scarce biologics, such as human growth hormone and insulin, commercially viable.
- The patent faced significant challenges and controversies, including disputes over obviousness, enablement, and infringement, highlighting the complex legal and scientific landscape of early biotechnology.
- US Patent 4,024,233 expired on May 17, 1994, and is now in the public domain, meaning the core technology it protected can be freely utilized.
- While the patent itself is no longer enforceable, it remains a critical historical document and prior art reference for ongoing innovation in the biopharmaceutical field, which is now protected by a vast network of subsequent patents.
Frequently Asked Questions
-
Does US Patent 4,024,233 still grant any exclusive rights for producing recombinant proteins?
No, US Patent 4,024,233 expired on May 17, 1994. The patent holder no longer has exclusive rights to the technology claimed.
-
Can companies today freely practice the methods described in US Patent 4,024,233?
Yes, as the patent has expired, companies are free to practice the methods claimed in US Patent 4,024,233 without infringing on this specific patent.
-
What role does US Patent 4,024,233 play in current patent landscapes?
The patent serves as essential prior art. While its claims are in the public domain, it informs the examination and validity of new patent applications in recombinant DNA technology, helping to define what is considered novel and non-obvious today.
-
Were there any major legal disputes directly concerning the validity of US Patent 4,024,233 itself?
While there were numerous disputes over infringement and licensing related to the patent, significant legal challenges directly questioning the validity of the patent’s original issuance based on prior art or enablement were part of the broader litigation environment surrounding its exploitation. Specific court rulings on validity would have been context-dependent within infringement cases.
-
If I am developing a new biopharmaceutical using recombinant technology, do I only need to consider expired patents like US Patent 4,024,233?
No, it is crucial to conduct a comprehensive freedom-to-operate analysis. Numerous other patents covering specific genes, protein sequences, vectors, expression systems, purification methods, and therapeutic uses are likely still active and must be considered to avoid infringement.
Citations
[1] Genentech, Inc. (1977). Process for the preparation of a proteinaceous substance (U.S. Patent No. 4,024,233). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
